A widely prescribed blood pressure drug was associated with a 33% higher risk of serious kidney problems in people with type 2 diabetes, even when they were already taking kidney-protective medications. The surprising finding is prompting researchers to question whether DCCBs are always the safest second-line choice for diabetic kidney disease.
New findings presented at the 63rd ERA Congress suggest that a commonly prescribed group of blood pressure drugs may be linked to worse kidney outcomes in people with type 2 diabetes (T2D), including patients already taking newer medications designed to protect kidney function.
The medications, known as dihydropyridine calcium-channel blockers (DCCBs), lower blood pressure by relaxing blood vessels. They are often prescribed as second-line treatments for people with diabetic kidney disease (DKD). In the new study, patients who took DCCBs in addition to standard therapies experienced a significantly greater risk of major adverse kidney events than patients treated with other blood pressure medications.
https://www.sciencedaily.com/releases/2026/08/260816044844.htm
